Twinject 0.3 is a drug owned by Impax Laboratories Llc. It is protected by 2 US drug patents filed in 2013 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Feb 04, 2025. Details of Twinject 0.3's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7621891 | Method and apparatus for delivering epinephrine |
Feb, 2025
(2 months from now) | Active |
| US7297136 | Medicine injection devices and methods |
Jan, 2025
(2 months from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Twinject 0.3's patents.
Latest Legal Activities on Twinject 0.3's Patents
Given below is the list of recent legal activities going on the following patents of Twinject 0.3.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 18 Dec, 2020 | US7621891 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 May, 2019 | US7297136 |
| Entity Status Set To Undiscounted (Initial Default Setting or Status Change) | 31 May, 2011 | US7297136 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Apr, 2010 | US7621891 |
| Change in Power of Attorney (May Include Associate POA) Critical | 20 Apr, 2010 | US7297136 |
| Correspondence Address Change Critical | 16 Apr, 2010 | US7297136 |
| Correspondence Address Change Critical | 16 Apr, 2010 | US7621891 |
| Patent Issue Date Used in PTA Calculation Critical | 24 Nov, 2009 | US7621891 |
| Recordation of Patent Grant Mailed Critical | 24 Nov, 2009 | US7621891 |
| Issue Notification Mailed Critical | 04 Nov, 2009 | US7621891 |
US patents provide insights into the exclusivity only within the United States, but Twinject 0.3 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Twinject 0.3's family patents as well as insights into ongoing legal events on those patents.
Twinject 0.3's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Twinject 0.3's generic launch date based on the expiry of its last outstanding patent is estimated to be Feb 04, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Twinject 0.3 Generic API suppliers:
Epinephrine is the generic name for the brand Twinject 0.3. 4 different companies have already filed for the generic of Twinject 0.3, with Am Regent having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Twinject 0.3's generic
Alternative Brands for Twinject 0.3
There are several other brand drugs using the same active ingredient (Epinephrine) as Twinject 0.3. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | ||
|---|---|---|---|
| Adamis Pharms Corp |
| ||
| Armstrong Pharms |
| ||
| Ars Pharms Operation |
| ||
| Baxter Hlthcare Corp |
| ||
| Bpi Labs |
| ||
| Endo Operations |
| ||
| Impax |
| ||
| Inforlife |
| ||
| Kaleo Inc |
| ||
| Long Grove Pharms |
| ||
| Mylan Speciality Lp |
| ||
| Vyteris |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Epinephrine, Twinject 0.3's active ingredient. Check the complete list of approved generic manufacturers for Twinject 0.3
About Twinject 0.3
Twinject 0.3 is a drug owned by Impax Laboratories Llc. Twinject 0.3 uses Epinephrine as an active ingredient. Twinject 0.3 was launched by Impax in 2009.
Approval Date:
Twinject 0.3 was approved by FDA for market use on 25 November, 2009.
Active Ingredient:
Twinject 0.3 uses Epinephrine as the active ingredient. Check out other Drugs and Companies using Epinephrine ingredient
Dosage:
Twinject 0.3 is available in injectable form for intramuscular, subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| EQ 0.3MG/DELIVERY | INJECTABLE | Discontinued | INTRAMUSCULAR, SUBCUTANEOUS |